For (b) and (c), values are shown as mean of n=2

For (b) and (c), values are shown as mean of n=2. of T2D. == Introduction == Type 2 diabetes (T2D) is usually a chronic illness of pandemic proportions affecting over 400 million people worldwide (www.idf.org). It is characterized by hyperglycaemia, resulting from the progressive loss of pancreatic -cell function in the presence of insulin resistance. Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of morbidity and mortality in T2D patients and is the largest contributor of direct and indirect costs of diabetes1. Treatment strategies are often multifactorial and target central ASCVD risk factors including poor glycaemic control, dyslipidaemia, obesity and hypertension. However less than 10% of patients achieve combined target goals2. To address this treatment space, we designed a proprotein convertase subtilisin/kexin type 9 (PCSK9) neutralizing monoclonal antibody (mAb) fused to a glucagon-like peptide-1 (GLP-1) receptor (GLP-1R) agonist peptide to deliver low-density lipoprotein cholesterol Cyclobenzaprine HCl (LDL-C) Cyclobenzaprine HCl lowering capabilities combined with glycaemic and excess weight Cyclobenzaprine HCl control in a single molecule. GLP-1 is usually a peptide hormone notably produced by the intestinal enteroendocrine L-cells of the gut. It is secreted following nutrient ingestion, resulting in Cyclobenzaprine HCl enhanced glucose-stimulated insulin secretion (GSIS) from your pancreatic -cells as well as delayed gastric emptying and enhanced satiety, making it a stylish target for the treatment of T2D and obesity3. GLP-1 is rapidly degraded by the dipeptidyl peptidase-4 enzyme (DPP-4) requiring the development of DPP-4 resistant peptide analogues to generate robust efficacy. ZC3H13 Continuous activity, compatible Cyclobenzaprine HCl with weekly dosing for improved individual convenience, was further achieved using slow release formulations or genetic fusion with a long half-life carrier protein as an antibody Fc or serum albumin4. GLP-1 receptor agonists (GLP-1RA) effectively reduce glycated haemoglobin (HbA1c), lower body excess weight and provide cardiovascular risk reductions5,6. To improve the cardiovascular benefits of GLP-1RAs, we elected to target LDL-C lowering by fusing a GLP-1 analogue peptide to a neutralizing PCSK9 monoclonal antibody. PCSK9 is usually a serum protein that binds to the LDL receptor and promotes its degradation, resulting in increased levels of LDL-C in blood circulation7. Anti-PCSK9 antibodies, such as evolocumab and alirocumab, block the PCSK9 conversation with LDL receptor and have demonstrated strong LDL-C reductions in hypercholesterolemic patients8. In addition, PCSK9 antibodies have shown an additive effect with statin therapy9and reduced the risk of cardiovascular events10. Here we describe the generation and preclinical evaluation of MEDI4166, a dual anti-PCSK9 antibody fused with a GLP-1 analogue agonist peptide, with the potential to provide significant benefit to T2D patients with high cardiovascular risk. As proof of concept that PCSK9/GLP-1 peptide-antibody molecules can deliver dual pharmacology, we investigated a panel of N-terminal genetic fusions of a DPP-4-resistant GLP-1 analogue with different PCSK9 antibodies and linkers. Numerous challenges had to be resolved through peptide engineering and pharmacokinetic-pharmacodynamic (PK-PD) modelling to develop MEDI4166. These included: improving thein vivostability of the GLP-1 analogue peptide which was significantly shorter than the antibody moiety; tuning the potency at GLP-1 receptor to achieve efficient and safe GLP-1 activity at doses compatible with strong PCSK9 suppression; and minimising the propensity of the fusion molecule to aggregate. == Results == == Dual function of GLP-1 receptor agonist peptide and anti-PCSK9 antibody fusions == Based on the crucial requirement for a free N-terminus around the GLP-1 peptide for receptor activation11, we genetically fused a DPP-4-resistant GLP-1R agonist peptide, similar to the one used in the Fc fusion molecule LY218926512, to either the heavy or light chain variable domain name of neutralising anti-PCSK9 antibodies (Fig.1a). We investigated a panel of seven antibodies, from multiple origins (Supplementary Table1) and of.